Mannkind (MNKD) Non-Current Receivables (2010 - 2014)
Mannkind (MNKD) reported Non-Current Receivables of $311000.0 for Q4 2014, up 4.36% year-over-year from $298000.0 in Q4 2013, and up 19.62% on a QoQ basis from $260000.0 in Q3 2014.
Mannkind (MNKD) has 5 years of Non-Current Receivables data on file, last reported at $311000.0 in Q4 2014.
- Quarterly Non-Current Receivables rose 4.36% year-over-year to $311000.0 in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $311000.0 (up 4.36% YoY) and the FY2014 annual result came in at $311000.0, up 4.36% from the prior year.
- Non-Current Receivables advanced to $311000.0 in Q4 2014 per MNKD's latest filing, from $260000.0 in the prior quarter.
- Across five years, Non-Current Receivables topped out at $885000.0 in Q2 2011 and bottomed at $223000.0 in Q3 2013.
- The 5-year median for Non-Current Receivables is $388500.0 (2011), against an average of $437375.0.
- The widest annual swing landed in 2012, when Non-Current Receivables tumbled 33.83%; it then grew 16.59% in 2014.
- Tracing MNKD's Non-Current Receivables over 5 years: stood at $629000.0 in 2010, then retreated by 24.8% to $473000.0 in 2011, then plunged by 33.83% to $313000.0 in 2012, then declined by 4.79% to $298000.0 in 2013, then increased by 4.36% to $311000.0 in 2014.
- Per Business Quant, the three latest MNKD Non-Current Receivables figures stand at $311000.0 (Q4 2014), $260000.0 (Q3 2014), and $463000.0 (Q2 2014).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 311,000.00 |
| Sep 30, 2014 | 260,000.00 |
| Jun 30, 2014 | 463,000.00 |
| Mar 31, 2014 | 380,000.00 |
| Dec 31, 2013 | 298,000.00 |
| Sep 30, 2013 | 223,000.00 |
| Jun 30, 2013 | 470,000.00 |
| Mar 31, 2013 | 391,000.00 |
| Dec 31, 2012 | 313,000.00 |
| Sep 30, 2012 | 293,000.00 |
| Jun 30, 2012 | 658,000.00 |
| Mar 31, 2012 | 565,000.00 |
| Dec 31, 2011 | 473,000.00 |
| Sep 30, 2011 | 386,000.00 |
| Jun 30, 2011 | 885,000.00 |
| Dec 31, 2010 | 629,000.00 |